Hodgkin Disease: all 914 studies

Page 2 of 10. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.

• A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT04665063Not applicable
• EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaRecruitingNCT04664179Phase 1
• First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)RecruitingNCT04638790Phase 3
• PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHLRecruitingNCT04624984Phase 2
• The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
• BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingNCT04378647Phase 2
• Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionRecruitingNCT04099966Phase 2
• Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2
• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 2
• Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.RecruitingNCT03500133Phase 4
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingNCT03418038Phase 2
• SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03250962Phase 2
• Auto Stem Cell Transplant for Lymphoma PatientsRecruitingNCT03125642Phase 2
• Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IIIRecruitingNCT03117036
• Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
• CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)RecruitingNCT02917083Phase 1
• Treatment for Classical Hodgkin Lymphoma in Children and AdolescentsRecruitingNCT02797717Not applicable
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT02682667
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsRecruitingNCT02508038Phase 1
• CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive LymphomasRecruitingNCT02259556Phase 1/2
• Prospective Cohort With Hemopathy in Languedoc-RoussillonRecruitingNCT02134574
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
• Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and LymphomaRecruitingNCT01788839
• Tissue Collection for Studies of Lymph CancerRecruitingNCT01676805
• Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALERecruitingNCT01555892Phase 1
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)RecruitingNCT01351545
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Biology Studies of Hematologic CancersEnrolling by invitationNCT00923442
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's DiseaseRecruitingNCT00398177
• Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
• Impact of Respiratory Training in Lymphoma SurvivorsTerminatedNCT05938127Not applicableResults posted
• Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLTerminatedNCT05883449Phase 2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedNCT05508867Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
• AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHLCompletedNCT05140382Phase 2Results posted
• Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)CompletedNCT05008224Phase 2Results posted
• Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)CompletedNCT04875195Phase 2Results posted
• Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaTerminatedNCT04788043Phase 2Results posted
• Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or LymphomaActive, not recruitingNCT04459416Phase 3Results posted
• Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"CompletedNCT04213209Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT04052997Phase 2Results posted
• A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
• Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among SurvivorsCompletedNCT03935282Not applicableResults posted
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingNCT03907488Phase 3Results posted
• TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic MalignanciesActive, not recruitingNCT03849651Phase 2Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03739619Phase 1/2Results posted
• Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"CompletedNCT03729609Results posted
• Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedNCT03646123Phase 2Results posted
• CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantActive, not recruitingNCT03560752Phase 1Results posted
• Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results posted
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin LymphomaCompletedNCT03331341Phase 1/2Results posted
• B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and OutcomesCompletedNCT03327571Results posted
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
• PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin LymphomaActive, not recruitingNCT03226249Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03209973Phase 2Results posted
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
• Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaActive, not recruitingNCT03179917Phase 2Results posted
• PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's LymphomaCompletedNCT03155425Phase 2Results posted
• Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial ResponseTerminatedNCT03154710Not applicableResults posted
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TerminatedNCT03138499Phase 3Results posted
• Study of Atezolizumab in Relapsed or Refractory Hodgkin LymphomaTerminatedNCT03120676Phase 2Results posted
• Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT03114683Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT03077828Phase 2Results posted
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
• Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HLActive, not recruitingNCT03016871Phase 2Results posted
• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruitingNCT02979522Phase 1/2Results posted
• Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedNCT02927769Phase 2Results posted
• Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin LymphomaTerminatedNCT02875067Phase 1/2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Carfilzomib and TGR-1202 in Treatment of R/R LymphomaTerminatedNCT02867618Phase 1/2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02824029Phase 2Results posted
• Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantActive, not recruitingNCT02797470Phase 1/2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• Administration of T Lymphocytes for Prevention of Relapse of LymphomasActive, not recruitingNCT02663297Phase 1Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)TerminatedNCT02603419Phase 1Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted

← Hodgkin Disease overview